Wilmington PharmaTech Launches $50 Million Expansion to Double U.S. Small-Molecule API Manufacturing Capacity in Delaware
Wilmington PharmaTech (“Wilmington”), a leading U.S.-based research, development, and manufacturing organization (CRDMO) focused on complex custom small-molecule API production, today announced a $50 million expansion of its Delaware campus to more than double its current API reactor capacity, supporting growing demand for high-quality, U.S.-based manufacturing.
Wilmington PharmaTech Appoints Seasoned Commercial Leader to Drive Growth
Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development and manufacturing organization (CRDMO) focused on complex custom small molecule API, today announced that it has appointed Mike Shearer to the role of Chief Commercial Officer, where he will play a pivotal role in driving growth, strengthening client partnerships, and furthering the organization’s position as a trusted partner for API development and manufacturing. Shearer will report to Hui-Yin “Harry” Li, Ph.D., WPT’s Founder and CEO.
Wilmington PharmaTech Appoints Industry Veteran Kent Payne as Managing Director and Board Member
Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development and manufacturing organization (CRDMO) focused on complex custom small molecule API, today announced the appointment of Kent Payne, Ph.D., as Managing Director and Board Member. Dr. Payne, an Operating Partner at Curewell Capital, a healthcare-focused private equity firm, joins WPT’s leadership team following Curewell’s recent investment in the company, and will work closely with WPT’s Founder and CEO Hui-Yin “Harry” Li, Ph.D., to accelerate the company’s growth strategy, including expanding manufacturing capacity and capabilities in the U.S.
